Respiratory Collaboration and Licensing Deals 2016-2023

$3,995.00

Respiratory Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2023

Publication date
October 2023
Number of pages
200+
Product type
Research report
Available formats
PDF document
Report edition
4
SKU
CP2213

Respiratory Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the respiratory deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of respiratory deals from 2016 to 2023.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of respiratory dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in respiratory dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the respiratory field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in respiratory dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of respiratory deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of respiratory deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in respiratory deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

Key benefits

Respiratory Collaboration and Licensing Deals provides the reader with the following key benefits:

  • Understand deal trends since 2016
  • Browse respiratory collaboration and licensing deals
  • Benchmark analysis – identify market value of transactions
  • Financials terms - upfront, milestone, royalties
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

 

Report scope

Respiratory Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of respiratory trends and structure of deals entered into by leading biopharma companies worldwide.

Respiratory Collaboration and Licensing Deals includes:

  • Trends in respiratory dealmaking in the biopharma industry
  • Overview of collaboration and licensing deal structure
  • Directory of respiratory deal records covering pharmaceutical and biotechnology
  • The leading respiratory deals by value
  • Most active respiratory licensing dealmakers

In Respiratory Collaboration and Licensing Deals, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Therapeutic area
  • Technology type

Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.

Respiratory Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Respiratory Collaboration and Licensing Deals provides the reader with the following key benefits:

  • Understand deal trends since 2016
  • Browse respiratory collaboration and licensing deals
  • Benchmark analysis – identify market value of transactions
  • Financials terms - upfront, milestone, royalties
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Trends in respiratory dealmaking

 

2.1. Introduction

2.2. Respiratory partnering over the years     

2.3. Respiratory partnering by deal type

2.4. Respiratory partnering by industry sector

2.5. Respiratory partnering by stage of development

2.6. Respiratory partnering by technology type

2.7. Respiratory partnering by therapeutic indication

 

Chapter 3 – Financial deal terms for respiratory partnering

 

3.1. Introduction

3.2. Disclosed financials terms for respiratory partnering

3.3. Respiratory partnering headline values

3.4. Respiratory deal upfront payments

3.5. Respiratory deal milestone payments

3.6. Respiratory royalty rates

 

Chapter 4 – Leading respiratory deals and dealmakers

 

4.1. Introduction

4.2. Most active in respiratory partnering

4.3. List of most active dealmakers in respiratory    

4.4. Top respiratory deals by value

 

Chapter 5 – Respiratory contract document directory

                                            

5.1. Introduction

5.2. Respiratory partnering deals where contract document available

 

Chapter 6 – Respiratory dealmaking by therapeutic target

 

6.1. Introduction

6.2. Deals by respiratory therapeutic target

 

Deal directory

 

Deal directory – Respiratory deals by company A-Z 2016 to 2023

Deal directory – Respiratory deals by technology type 2016 to 2023

 

Deal type definitions

 

About Wildwood Ventures

 

Current Partnering

Current Agreements

Recent report titles from CurrentPartnering

 

Table of figures

 

Figure 1: Respiratory partnering since 2016

Figure 2: Respiratory partnering by deal type since 2016

Figure 3: Respiratory partnering by industry sector since 2016

Figure 4: Respiratory partnering by stage of development since 2016

Figure 5: Respiratory partnering by technology type since 2016

Figure 6: Respiratory partnering by indication since 2016

Figure 7: Respiratory deals with a headline value

Figure 8: Respiratory deals with upfront payment values

Figure 9: Respiratory deals with milestone payment

Figure 10: Respiratory deals with royalty rates

Figure 11: Active respiratory dealmaking activity since 2016

Figure 12: Top respiratory deals by value since 2016

Pricing options

  • $3,995: single-user (encrypted file - one user/device)
  • $5,995: multi-user (encrypted file - up to 5 users/devices)
  • $9,995: company (unencrypted file)

Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.

Company license files are not encrypted and can be accessed using a PDF Reader.

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by Evalon.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

 

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

4D Molecular Therapeutics, AazeinTx, Abbvie, Abionic, ABVC BioPharma, Acceleron Pharma, Acrobat Genomics, Actelion, AdAlta, Adalvo, Adamis Pharmaceuticals, adMare BioInnovations, ADM Tronics, Advanz Pharma, Advent Therapeutics, Aerami Therapeutics, Aerogen, AeroRx Therapeutics, Aerpio Pharmaceuticals, AgeX Therapeutics, Aidoc, AIT Therapeutics, Akari Therapeutics, Akonni Biosystems, Alex Therapeutics, Allakos, Allegheny Technologies, Allinaire Therapeutic, Alpine Immune Sciences, Altavant Sciences, Altum Pharmaceuticals, Aluna, Alvotech, American Association for Laboratory Accreditation, American College of Chest Physicians, American Lung Association, Amneal Pharmaceuticals, AMO Pharma, Amyndas Pharmaceuticals, Analytics 4 Life, AnGes MG, Anthem, Anthem Bluecross, Apple, Aptar Pharma, Aptuit, Arch Biopartners, Arcturus Therapeutics, Arena Pharmaceuticals, Aridis Pharmaceuticals, Aristea Therapeutics, Ark Biosciences, ArtiQ, ARUP Laboratories, AssisTek, Asthma UK, AstraZeneca, Athersys, Atrapos Therapeutics, aTyr Pharma, Avicenna Technology, Avrobio, AzarGen Biotechnologies, Bausch Health Companies, Bayer, Baylor Health Care System, Beijing Tide Pharmaceutical, Ben-Gurion University, BenevolentAI, Be The Match BioTherapies, Beth Israel Deaconess Medical Center, BetterLife Pharma, Bicycle Therapeutics, Bill and Melinda Gates Foundation, Bio-Me, Bio-Techne, Bioforum, BioKey, BioLink Life Sciences, BioLum Sciences, Biomedical Advanced Research and Development Authority, BioMed X Innovation Center, BiosanaPharma, BioVersys, Blu Biotech, Blue Cross Blue Shield Association, Blue Shield of California, BNC Korea, Boehringer Ingelheim, Bonne Santé Group, Boomer Esiason Foundation, Boston Scientific, Boston University School of Medicine, Brainomix, Breath Therapeutics, Bridge Biotherapeutics, Brigham and Women's Hospital, BrightInsight, Bristol-Myers Squibb, British Lung Foundation, Broncus Technologies, Brown University, C4X Discovery, California Institute for Biomedical Research, California Institute for Regenerative Medicine, Cambridge Healthcare Innovations, Cannex Scientific, Cantex Pharmaceuticals, CARB-X, Cardiovascular Systems, Carnegie Mellon University, Cedars-Sinai Medical Center, Celgene, Cellect Biotechnology, CELLINK, Cellix Bio, Celltrion, Celularity, Charak Foundation, Charite Universitatsmedizin Berlin, Chiesi Farmaceutici, Children's Hospital Boston, Chronolife, Cilag AG, Cincinnati Children’s Hospital Medical Center, Cipla, Circassia, Citius Pharmaceuticals, Clalit Health Services, Clario, CN Bio, Coalition for Epidemic Preparedness Innovations, Coeptis Therapeutics, CohBar, Collplant, Combioxin, Commense, Commonwealth of Pennsylvania, Context Therapeutics, COPD Foundation, Corsair Pharma, Cosmo Pharmaceuticals, Covalon Technologies, CRS Bio, CrystecPharma, CSL Behring, CS Pharmaceuticals, Cue Health, Curadev Pharma, Curetis, CureVac, CVD Equipment, CytoReason, Cytovation, Daewoong Pharmaceutical, Dalton Pharma Services, Department of Defense, Dermira, Deverra Therapeutics, DevPro Biopharma, Diffusion Pharmaceuticals, Diomics, Donnelley Financial Solutions, Duke Clinical Research Institute (DCRI), Duke University, Dymax, Eagle Pharmaceuticals, Edesa Biotech, Eisai, Empatica, ENA Respiratory, Endpoint Health, Enzyvant Science, Epistemic AI, Erasmus University Medical Center, Ethris, European Union, Everest Medicines, EvolveImmune Therapeutics, Evommune, Experimental Therapeutics Centre of Singapore, Fannin, Faron Pharmaceuticals, Fibrocor Therapeutics, FibroGenesis, Florica Therapeutics, Fluidda, fluidIQ, Food and Drug Administration (FDA), Forge Therapeutics, Foundation for Sarcoidosis Research, Fred Hutchinson Cancer Research Center, Fujifilm Diosynth Biotechnologies, FUJIFILM SonoSite, Fulcrum Therapeutics, Fusion Genomics, Galapagos, Gatehouse Bio, Geisinger Health System, GEn1E Lifesciences, Genentech, GenScript ProBio, Genten Therapeutics, German Government, Gilead Sciences, Glenmark Pharmaceuticals, Glenmark Pharmaceuticals S.A., Global Coalition for Adaptive Research, GlobalLogic, Government of Israel, Graviton Bioscience, Green Park Collaborative, Grifols, GSK, Guangzhou Institute of Respiratory Disease, Hangzhou Chance Pharmaceuticals, Haplogen, Harbour Biomed, Harvard Stem Cell Institute, Harvard University, Harvest Capital Strategies, HCmed Innovations, Healios K.K., Healium Medical, Health Care Originals, HealthPrize Technologies, HealthSnap, Hebrew University of Jerusalem, Hemovent, Henry M. Jackson Foundation, Highmark Health, Hikma Pharmaceuticals, Honeywell, Hong Kong Polytechnic University, Hoth Therapeutics, Humanetics, Hyfe, i2c Pharmaceutical Services, iBio, IBM, Icagen, Iconovo, IDbyDNA, IDT Biologika, Illumina, Imbio, Immune Therapeutics, Imperial College London, Inari Medical, Industrial Technology Research Institute, Inhalation Sciences, Inhalon Biopharma, Inhibrx, Innovare, Innovate UK, Innova Vascular, Innovus Pharmaceuticals, Inovio Pharmaceuticals, Inovytec, Insmed Inc, Inspira Technologies, Instem, Integrated Computer Solutions, Intrexon, Inventiva, InVixa, Itamar Medical, Janssen Pharmaceuticals, Janssen Research & Development, Janssen Sciences, Jiangsu QYuns Therapeutics, Johannes Gutenberg University, Johns Hopkins University, Johnson & Johnson Innovation, Kaleido Biosciences, Kamada, KangWon University Institute of Medical Science, KARE Biosciences, Karolinska Institute, Kennedy Institute of Rheumatology, Keyence, Kindeva Drug Delivery, Knopp Biosciences, Koye Pharmaceuticals, Kyorin Pharmaceutical, La Jolla Institute for Allergy & Immunology, Lassen Therapeutics, Laurel Venture Capital, Leading BioSciences, Lee's Pharmaceutical, Leidos, LEO Pharma, LianBio, LifeArc, Ligand Pharmaceuticals, Light Chain Bioscience, LightDeck Therapeutics, Lipigon Pharmaceuticals, Locus Biosciences, Lotus Pharmaceuticals, Lumen Biomedical, Luminex, Lundquist Institute, Lung Biotechnology, Lung Therapeutics, Lung Transplant Foundation, Lurie Children's Hospital of Chicago, Lyomark Pharma, Lyra Therapeutics, Macau University of Science and Technology, MannKind Biopharmaceuticals, Marinomed Biotechnologie, Massachusetts General Hospital, Matrix Biomed, Mayo Clinic, Medical International Research, Medical Technology Enterprise Consortium, Medicines Discovery Catapult, MediciNova, MedImmune, MediPines, Meissa Vaccines, Melinta Therapeutics, Melior Pharmaceuticals, Menarini, Menarini Asia-Pacific, Merck and Co, Mesoblast, Methapharm, Microbio Shanghai, Moderna, Momenta Pharmaceuticals, Monopar Therapeutics, Morphic Therapeutic, Mount Sinai Health System, Mundipharma, Mylan Pharmaceuticals, Myovant Sciences, Nanopharm, NanoString Technologies, NantKwest, Nanyang Technological University, Nashville Biosciences, National Healthcare Services (NHS), National Health Service, National Heart, Lung and Blood Institute, National Institute for Environmental Health Sciences, National Institute of Allergy and Infectious Diseases, National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health, National Jewish Health, National Kidney Foundation, National Organization for Rare Disorders, National Research Council Canada, National Science Foundation, Nepean Blue Mountains Local Health District’s Nepean Hospital, Nephron Pharmaceuticals, NeuCen BioMed, Neurocare Group, NeuroRx, Nexel, NitricGen, Nitto Denko, North Carolina State University, NorthStar Medical Radioisotopes, Northwestern University, Novartis, NoveCite, Novellus Therapeutics, NRx Pharmaceuticals, NTC, Nuance Pharma, Numedicus, NuMedii, NuvoAir, ObvioHealth, Olympus Respiratory America, Omdana Therapeutics, Oneness Biotech, OpGen, Organicell Regenerative Medicine, Orgenesis, Orion, Oslo University Hospital, Owkin, Owlstone Medical, Palisade Bio, Pantherics, Paragonix Technologies, Paratek Pharmaceuticals, PARI Pharma, Partner Therapeutics, Patara Pharma, Patient-Centered Outcomes Research Institute, Peking University, Penumbra, Perrigo, Pharmbio Korea, Philips, Pieris Pharmaceuticals, Pluristem Therapeutics, Polarean Imaging, Polyphor, Precision Image Analysis, Propeller Health, ProQR Therapeutics, Protalix BioTherapeutics, Pulmatrix, Pulmodyne, Pulmonary Fibrosis Foundation (PFF), Pulmonomy, PulmoSIM Therapeutics, Pulthera, Punjab Province, PureTech Health, QOL Devices, Quartesian Clinical Research, Quebec Government, Quercis Pharma, R4D Biotech, RapidAI, ReAlta Life Sciences, Recipharm, Recludix Pharma, Recurrent Respiratory Papillomatosis Foundation, RedHill Biopharma, Redox, Redx Pharma, Renovion, Respira Therapeutics, RespiraWorks, RespireRx Pharmaceuticals, resTORbio, Revon Systems, Roche, Roivant Sciences, Royal Philips Electronics, RS BioTherapeutics, Rubedo Life Sciences, RxCap, Samumed, Sandoz, Sanofi, Santhera Pharmaceuticals, SarcoMed USA, Savana, Savara Pharma, Scholar Rock, Science 37, Seelos Therapeutics, Sema4, Sensible Medical Innovations, SenzaGen, Seqirus, Seqster, Serum Institute of India, Shandong Luoxin Pharma, Shaperon, Sheba Medical Center, Shenzhen Institutes of Advanced Technology, Siemens Healthineers, Silence Therapeutics, Simulations Plus, Siolta Therapeutics, SiteOne Therapeutics, Sleepiz, Sonde Health, Sonmol, Sosei Heptares, SpeeDx, Spesana, Spire Health, SQI Diagnostics, Stanford University School of Medicine, Statera Biopharma, Stemedica Cell Technologies, Stevanato, Stimit, Strados Labs, Sumitomo Dainippon Pharma, Sumitovant Biopharma, Sunnybrook Research Institute, Sunovion Pharmaceuticals, SUNY Upstate Medical University, Sutter Health, Synergie Lyon Cancer, Synthonics, Taiba, Taiho, Takeda Pharmaceutical, TARGET PharmaSolutions, TB Alliance, Tektronix Component Solutions, Telesair, Tetra Bio-Pharma, Teva Pharmaceutical Industries, Texas Lung Injury Institute, TFF Pharmaceuticals, The Alfred Hospital, Therma Bright, Thermo Fisher Scientific, Third Pole Therapeutics, Three Lakes Foundation, Tivic Health Systems, TMM Software, toSense, Transpire, Trevena, TrialSpark, United Therapeutics, University of California, Davis, University of California, San Diego, University of California San Francisco, University of Chicago, University of Dundee, University of Florida, University of Houston, University of Manchester, University of Maryland Baltimore, University of Melbourne, University of Michigan, University of Montana, University of Munster, University of Oklahoma, University of Oxford, University of Pennsylvania, University of Pittsburgh, University of Pittsburgh Medical Center, University of Sheffield, University of Texas at El Paso, University of Texas Health Science Center at Tyler, University of Virginia, University of Wisconsin, Urovant Sciences, US Army Medical Research and Material Command, Utrecht University, UWM Research Foundation, Vanderbilt University, Vapotherm, Vasomune Therapeutics, Vectura, Veeva Systems, VenatoRx, Veracyte, Verantos, Verily, Verona Pharma, Vicore Pharma, Vida Diagnostics, Virginia Catalyst, Vituity, Viz.ai, Vocalis Health, Vortran Medical, WaVe Lifesciences, Weill Cornell Medical College, Windtree Therapeutics, Wuxi STA, Wyss Institute, Xerox, XL-Protein, Xvivo Perfusion, Xylyx Bio, Yale School of Medicine, Yale University, Yissum Research Development, ZappRx, Zentiva, ZEPHYRx, Zymedi

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.